KOL Insight

Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – Spain

A Spain-based KOL opines about the most used agents in wet AMD with particular emphasis on the effect of cost and safety in making prescribing decisions. During the discussion, the KOL gives a glimpse of what the future might hold in terms of newer agents and combination therapy. The KOL also speaks about novel modes of administration and the impact of these on the current market.

Seizure Pulse Survey

Eslicarbazepine has been approved in ex-US markets including the EU for years.

We surveyed 10 US Neurologists to determine prelaunch perceptions of Aptiom.